Results for weight-loss drug targeting amylin find similar efficacy across different doses and high rates of side effects, ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk (NYSE: NVO) stock had a Monday to forget, as news from a top rival dampened sentiment on the Danish ...

Dilok Klaisataporn Most major stock indexes across the globe ended the week lower, following US-China trade talks and renewed ...

Novo Nordisk is making moves to retain its market share in the weight loss space after Eli Lilly's tirzepatide won a ...

Wednesday marked a losing session on Wall Street, with the S&P 500 snapping its three-day win streak, as did the Nasdaq ...

Get Gold mangalsutra News on Telangana Today, Gold mangalsutra latest news, Gold mangalsutra news, | Telangana Today ...

In the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NYSE: NVO). The two companies have approved weight loss drugs that are generating billions ...

Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force behind its strong numbers. It may not be long before Novo Nordisk also ...

Novo Nordisk's profit of DKK28.23 billion also topped estimates. Wegovy sales soared 107% at constant exchange rates to DKK19.87 billion, just below estimates. Ozempic sales rose 12% to DKK33.85 ...